Oruka Therapeutics (ORKA) return on equity (ROE)

Return on equity · fiscal 2025
-22.3%

Oruka Therapeutics (ORKA) earned a return on equity of -22.3% in fiscal 2025 (the year ended December 31, 2025). Figures as of 17 Nov 2026, 21:34 UTC, from the company's filings with the SEC and Yahoo Finance.

Key facts

Return on equity, fiscal 2025
-22.3%
Highest on record
-14.4%fiscal 2023
Lowest on record
-180.0%fiscal 2017
Fiscal years on record
162009–2025

Figures as of . Older fiscal years come from the company's filings with the SEC, recent ones from Yahoo Finance. Figures, not advice.

Oruka Therapeutics return on equity (ROE), in more detail

Across the 16 fiscal years on record (2009–2025), the highest was -14.4% in fiscal 2023 and the lowest -180.0% in fiscal 2017. The fiscal 2025 figure is higher than in 87% of the 15 earlier fiscal years on record, whose median is -72.0%.

History · 16 fiscal years

Return on equity by fiscal year

Oruka Therapeutics return on equity (ROE), year by year

Oruka Therapeutics (ORKA) return on equity (ROE) by fiscal year
Fiscal yearReturn on equityChangeYear ended
2025-22.3%—
2023-14.4% 9.4 pts up
2022-23.8% 14.0 pts up
2021-37.9% 16.9 pts down
2020-20.9% 51.1 pts up
2019-72.0% 59.5 pts up
2018-131.5% 48.4 pts up
2017-180.0% 105.9 pts down
2016-74.1% 44.0 pts down
2015-30.1% 35.7 pts up
2014-65.7% 21.2 pts down
2013-44.5% 104.1 pts up
2012-148.6% 55.0 pts down
2011-93.6% 30.8 pts up
2010-124.4% 1.1 pts down
2009-123.3%—

Change is on the fiscal year before, in percentage points; a dash means that year is not on record. A dash anywhere else means the figure was not reported or cannot be computed — it is never filled in.

Method

How it is calculated

Return on equity is net income divided by shareholders' equity at the fiscal year-end; it is left blank when equity is negative.

How to read it

It is the profit earned on the owners' capital — above about 15% is strong, though heavy debt or large buybacks can inflate it.

Return on equity at health care companies of similar size

Return on equity of Oruka Therapeutics and comparable companies
CompanyReturn on equityFiscal year
Immunovant IMVT-59.3%2026
Axsome Therapeutics AXSM-207.5%2025
Chemed CHE27.1%2025
Oruka Therapeutics ORKA-22.3%2025
Arrowhead Pharmaceuticals ARWR-1439.4%2026
MSA Safety MSA20.4%2025

The latest fiscal year on record for each company, in the currency it reports in. Fiscal years end at different times of year.

More on ORKA

Oruka Therapeutics, figure by figure

Oruka Therapeutics (ORKA) overview: price, valuation and scorecardAll health care companies by market value

Oruka Therapeutics return on equity (ROE): questions and answers

What is Oruka Therapeutics's return on equity?

Oruka Therapeutics (ORKA) earned a return on equity of -22.3% in fiscal 2025 (the year ended December 31, 2025).

Is Oruka Therapeutics's return on equity high or low compared with its own history?

The fiscal 2025 figure is higher than in 87% of the 15 earlier fiscal years on record, whose median is -72.0%.

What are the highest and lowest return on equity figures on record for Oruka Therapeutics?

Across the 16 fiscal years on record (2009–2025), the highest was -14.4% in fiscal 2023 and the lowest -180.0% in fiscal 2017.

How is Oruka Therapeutics's return on equity calculated?

Return on equity is net income divided by shareholders' equity at the fiscal year-end; it is left blank when equity is negative.

Fiscal years are named for the calendar year they end in.

Cite this page

Funkfolio, “Oruka Therapeutics (ORKA) return on equity (ROE)”, data as of 17 November 2026. https://funkfolio.com/stock/ORKA/roe

Underlying data: the company's filings with the SEC and Yahoo Finance.